

## Part VI: Summary of the risk management plan

### Summary of risk management plan for Paracetamol/Caffein Orifarm (paracetamol/caffeine)

This is a summary of the risk management plan (RMP) for Paracetamol/Caffein Orifarm. The RMP details important risks of Paracetamol/Caffein Orifarm, and how more information will be obtained about Paracetamol/Caffein Orifarm's risks and uncertainties (missing information).

Paracetamol/Caffein Orifarm's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Paracetamol/Caffein Orifarm should be used.

Important new concerns or changes to the current ones will be included in updates of Paracetamol/Caffein Orifarm's RMP.

#### I. The medicine and what it is used for

Paracetamol/Caffein Orifarm is indicated in adults and children aged 12 and over (min. 40 kg) for short-term treatment of fever, e.g. in connection with colds and flu as well as mild to moderate pain, e.g. headache, toothache, menstrual pain and muscle and joint pain (see SmPC for the full indication). It contains paracetamol and caffeine as the active substances and it is administrated orally as a film-coated tablet.

#### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Paracetamol/Caffein Orifarm, together with measures to minimise such risks and the proposed studies for learning more about Paracetamol/Caffein Orifarm's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## ***II.A List of important risks and missing information***

Important risks of Paracetamol/Caffein Orifarm are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Paracetamol/Caffein Orifarm. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	Central nervous system related effects due to concomitant use of caffeine in excessive amounts (by dietary intake)
Important potential risks	Use in pregnancy and lactation
Missing information	None

## ***II.B Summary of important risks***

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## ***II.C Post-authorisation development plan***

### ***II.C.1 Studies which are conditions of the marketing authorisation***

There are no studies which are conditions of the marketing authorisation or specific obligation of Paracetamol/Caffein Orifarm.

### ***II.C.2 Other studies in post-authorisation development plan***

There are no studies required for Paracetamol/Caffein Orifarm.